What are the indications, dosing regimens, and monitoring recommendations for amphotericin B in serious systemic fungal infections?

Amphotericin B: Clinical Overview

Amphotericin B remains the gold standard for serious, life-threatening systemic fungal infections, with liposomal formulations preferred over conventional amphotericin B deoxycholate due to significantly reduced nephrotoxicity while maintaining equivalent efficacy. 1, 2

Primary Indications

Amphotericin B is specifically indicated for progressive, potentially life-threatening fungal infections including 2:

• Invasive aspergillosis
• Cryptococcosis (including CNS disease)
• Systemic candidiasis (resistant strains)
• Blastomycosis
• Coccidioidomycosis
• Histoplasmosis
• Mucormycosis (zygomycosis)
• Sporotrichosis

Critical caveat: Do not use amphotericin B for non-invasive infections like oral thrush, vaginal candidiasis, or esophageal candidiasis in immunocompetent patients 2.

Formulation Selection & Dosing

Liposomal Amphotericin B (L-AmB) - Preferred First-Line

For CNS Candidiasis/Cryptococcosis:

• 5 mg/kg IV daily (standard CNS infections) 1
• 10 mg/kg IV daily (mucormycosis with CNS involvement) 3
• Combine with flucytosine 25 mg/kg four times daily when appropriate 1

For Candida Endophthalmitis (resistant isolates):

• 3-5 mg/kg IV daily ± flucytosine 1
• Add intravitreal amphotericin B deoxycholate 5-10 μg/0.1 mL for macular involvement 1

For Mucormycosis:

• 5 mg/kg/day (no CNS involvement) 3
• 10 mg/kg/day (with CNS involvement) 3
• Duration: 4-6 weeks induction/consolidation, then 3-6 months maintenance 3

For Empiric Therapy in ICU:

• 3-5 mg/kg IV daily when echinocandins/azoles contraindicated 4, 1

Amphotericin B Deoxycholate - Alternative When Lipid Formulations Unavailable

For Neonatal Disseminated Candidiasis:

• 1 mg/kg IV daily (strong recommendation) 1

For Neonatal CNS Candidiasis:

• 1 mg/kg IV daily initially 1
• Alternative: Liposomal AmB 5 mg/kg daily 1

For Cystitis (Fluconazole-Resistant):

• 0.3-0.6 mg/kg IV daily for 1-7 days 1
• Bladder irrigation: 50 mg/L sterile water daily × 5 days (alternative) 1

For Mucormycosis (Alternative):

• 1-1.5 mg/kg/day IV over 6-8 hours 3
• Premedicate with diphenhydramine or acetaminophen 3
• Give 1L normal saline before and after infusion to reduce nephrotoxicity 3

For Blastomycosis:

• 0.7-1 mg/kg IV daily for 1-2 weeks, then step-down to itraconazole 5

General Dosing Principles:

• Maximum daily dose: 1.5 mg/kg - exceeding this risks fatal cardiac arrest 2
• Infuse over 2-6 hours at concentration of 0.1 mg/mL (1 mg/10 mL) 2
• Test dose: 1 mg in 20 mL over 20-30 minutes, monitor vitals every 30 minutes × 2-4 hours 2
• Start therapy at 0.25 mg/kg/day in stable patients, 0.3 mg/kg/day in severe/rapidly progressive infections 2
• Increase gradually by 5-10 mg/day to target 0.5-0.7 mg/kg/day 2

Critical Monitoring Requirements

Renal Function (most important):

• Monitor serum creatinine and creatinine clearance frequently throughout therapy 2
• Hydration and sodium repletion before administration reduces nephrotoxicity risk 2

Additional Laboratory Monitoring:

• Liver function tests
• Serum electrolytes (particularly magnesium and potassium - hypokalemia common) 2
• Complete blood counts
• Hemoglobin concentrations 2

Clinical Monitoring:

• Temperature, pulse, respiration, blood pressure during infusion 2
• Acute reactions (fever, chills, hypotension) common 1-3 hours post-infusion, diminish with subsequent doses 2

Important Clinical Pitfalls

1. Avoid rapid IV infusion - associated with hypotension, hypokalemia, arrhythmias, and shock 2

2. Separate from leukocyte transfusions - acute pulmonary reactions reported; temporally separate infusions as far as possible 2

3. Hypokalemia management - amphotericin B-induced hypokalemia potentiates digitalis toxicity and cardiac dysfunction; monitor closely if patient on corticosteroids or digitalis 2

4. Therapy interruption >7 days - restart at lowest dose (0.25 mg/kg) and titrate up gradually 2

5. Lipid formulations differ substantially - liposomal AmB achieves higher CNS levels than other lipid formulations, making it preferred for CNS infections 5, 6

6. Urinary tract involvement - use lipid formulations with caution in urinary candidiasis; amphotericin B deoxycholate may be preferred 1

Comparative Efficacy & Safety

The lipid formulations provide equivalent efficacy to conventional amphotericin B with significantly reduced nephrotoxicity 6, 7. Liposomal amphotericin B demonstrates superior tolerability with fewer infusion-related reactions compared to both conventional amphotericin B and other lipid formulations 7. Response rates across formulations remain approximately 50-70% for invasive fungal infections regardless of dose, though higher doses may improve tissue fungal eradication 8.